Our mission is to ensure promising cancer treatments
are tested on the right patients so effective drugs
can prove their true potential and reach FDA approval.
01 - The Problem
Only 3.5% of cancer drugs reach FDA approval
Most don't fail because they don’t work.
They fail because the wrong patients are enrolled.
When patient biology doesn't match the drug,
true signals are lost.
Effective therapies appear ineffective.
Trials fail for the wrong reason.
Cancer is complex.
Selection is still blind.
Clinicians can detect cancer.
They cannot see which cells will resist
treatment.
Critical tumour biology remains invisible
before enrollment.
Without that visibility, matching patients to
therapy is guesswork.
02 - The Solution
Trial enrollment doesn't have to be blind.
CellaraRx detects what standard methods miss.
CellaraRx analyzes tumor biology at the single-cell level before enrollment - revealing whether a patient is truly a match for the drug being tested.
✔ Identifies treatment-resistant cells before trial enrollment
✔ Maps where key cell types exist within the tumour
✔ Predicts likelihood of response before the trial begins
03 - The Results
Better trials.
Lower risk.
Higher confidence.
✔
Drug Developers
✔ Select the right patients before trials begin
✔ Reduce false negatives that kill viable drugs
✔ Make faster decisions with real confidence
✔
Pharma Investors
✔ De-risk drug development investments
✔ Deploy capital with signal, not guesswork
✔ Increase probability of trial success
✔
Cancer Patients
✔ Faster access to therapies that actually work
✔ Fewer failed treatments
✔ More precise matching to the right therapy
04 - The Process
Select the right patients
1 - Define trial criteria
We review your target profile and trial design.
2 - Analyze tumour biology
We identify patients are aligned with the therapy.
3 - Enroll with confidence
Only patients with a high likelihood of response move forward.